# A Study to Test a New Immunotherapy, ABX-001, Alone and in Combination With the Marketed Drug, Pembrolizumab, for the Treatment of Tumors Previously Treated With Other Therapies

> **NCT07231458** · PHASE1 · RECRUITING · sponsor: **Abalos Therapeutics GmbH** · enrollment: 27 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** ABX-001
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT07231458
- **Lead sponsor:** Abalos Therapeutics GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-14
- **Primary completion:** 2026-10-30
- **Final completion:** 2026-10-30
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2026-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07231458

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07231458, "A Study to Test a New Immunotherapy, ABX-001, Alone and in Combination With the Marketed Drug, Pembrolizumab, for the Treatment of Tumors Previously Treated With Other Therapies". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT07231458. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*